electroCore, Inc. Provides Update on nVNS to Treat Post Traumatic Stress Disorder
December 14, 2021 08:00 ET
|
electroCore, Inc.
ROCKAWAY, NJ, Dec. 14, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today provided an update on the ongoing...
electroCore Announces New Patent for Stroke and TIA Treatment
December 13, 2021 08:55 ET
|
electroCore, Inc.
ROCKAWAY, NJ, Dec. 13, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that the United States Patent...
electroCore to Participate at Canaccord Genuity MedTech & Diagnostics Forum
November 11, 2021 08:00 ET
|
electroCore, Inc.
ROCKAWAY, NJ, Nov. 11, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that its management team will be...
electroCore Announces Third Quarter 2021 Financial Results
November 04, 2021 16:01 ET
|
electroCore, Inc.
Third quarter 2021 revenue grew 17% sequentially and 38% over third quarter 2020 Company to host a conference call and webcast today, November 4, 2021 at 4:30 pm ET ROCKAWAY, N.J., Nov. 04, 2021 ...
electroCore to Announce Third Quarter 2021 Financial Results on Thursday, November 4th
October 21, 2021 08:00 ET
|
electroCore, Inc.
ROCKAWAY, NJ, Oct. 21, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, announced that it will report financial results for the third...
electroCore Announces Publication Reviewing the Prescribing of gammaCore for the Treatment of Cluster Headache in England
October 20, 2021 08:00 ET
|
electroCore, Inc.
ROCKAWAY, NJ, Oct. 20, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the publication of a peer-reviewed paper entitled...
electroCore Announces Regulatory Approval in Canada to Treat Adolescent Migraine
October 14, 2021 08:00 ET
|
electroCore, Inc.
ROCKAWAY, NJ, Oct. 14, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that the company received an amended Medical...
electroCore Provides Business Update and Select Third Quarter 2021 Financial Guidance
October 12, 2021 08:00 ET
|
electroCore, Inc.
Third quarter 2021 revenue expected to be approximately $1.5 millionNet cash used to fund operations in the third quarter 2021 of approximately $3.5 million ROCKAWAY, NJ, Oct. 12, 2021 (GLOBE...
electroCore Announces Acceptance of Motion to Dismiss in the Federal Court Securities Class Action Suit
October 07, 2021 08:00 ET
|
electroCore, Inc.
ROCKAWAY, NJ, Oct. 07, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced the granting of the company’s motion to dismiss the...
electroCore Presentation at the Cantor Fitzgerald Virtual Global Healthcare Conference
September 30, 2021 09:05 ET
|
electroCore, Inc.
ROCKAWAY, NJ, Sept. 30, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that its presentation at the...